

Barcelona, February 5, 2015

SIGNIFICANT EVENT

NOTIFICATION ON THE ACLIDINIUM BROMIDE FRANCHISE IN THE USA AND CANADA

Almirall, S.A. (ALM.MC), as per section 82 of the Securities Market Act (Ley 24/1988 on 28 July, that regulates the Stock Market or *Mercado de Valores* in Spain) and other applicable provisions, hereby announces that:

Almirall has agreed for AstraZeneca to acquire the US and Canada rights for acclidinium bromide from Actavis.

Upon completion of the transaction, AstraZeneca will own the development and commercial rights in the US and Canada to Tudorza™ Pressair™ (aclidinium bromide inhalation powder), a twice-daily long-acting muscarinic antagonist (LAMA) for chronic obstructive pulmonary disease (COPD), as well as assuming the development rights and obligations in the US and Canada for LA40464, the combination of a fixed dose of acclidinium with formoterol long acting beta agonist (LAMA / LABA) in a dry powder inhaler, which is approved in the EU under the brand name Duaklir® Genuair®.

The strategic transaction strengthens AstraZeneca's respiratory franchise globally and builds on the transaction with Almirall's respiratory portfolio in 2014, by extending the company's development and commercialization rights into the US and Canada for both Tudorza™ Pressair™ and Duaklir® Genuair®.

The focus and expertise of AstraZeneca in Respiratory and its commitment to support the development of the combination, will allow better opportunities to maximize the potential of acclidinium franchise in those two important markets.

Yours sincerely,

Pablo Divasson del Fraile

Investor Relations Department
investors@almirall.com

